<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04068077</url>
  </required_header>
  <id_info>
    <org_study_id>2018-10-019A</org_study_id>
    <nct_id>NCT04068077</nct_id>
  </id_info>
  <brief_title>Application of High Resolution Optical Coherence Tomography in Skin Disease: Amyloidosis and Differential Diagnosis</brief_title>
  <official_title>Application of High Resolution Optical Coherence Tomography in Skin Disease: Amyloidosis and Differential Diagnosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Apollo Medical Optics, Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Taipei Veterans General Hospital, Taiwan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Amyloidosis is caused by the misfolding protein accumulated in tissue, which affects the
      function of the organs. In addition to the primary cutaneous amyloidosis, a skin lesion may
      also appear in another classification - systemic amyloidosis. Physicians can confirm
      diagnosis of the above classification by skin biopsy.

      Primary cutaneous amyloidosis is common in Asia and South America. In Taiwan, 80 people are
      diagnosed with primary cutaneous amyloidosis in every 100,000 people. Among the disease,
      macular amyloidosis and lichen amyloidosis are the most common subtypes. Primary cutaneous
      amyloidosis can cause severe itching, pigmentation, and skin keratosis, and further affect
      the social behavior of patients. The etiology of primary cutaneous amyloidosis is currently
      unclear, possibly due to genetic variations or viral infection. Typical primary cutaneous
      amyloidosis can be diagnosed by clinical manifestations, however, if the location or
      appearance of a lesion is atypical, the disease will be indistinguishable from other
      pigmented diseases, and further need a biopsy. If physicians can use a rapider and more
      accurate assistance tool to evaluate disease first, it will improve the accuracy of clinical
      diagnosis, relieve patient of suffering from biopsy, and further use medical resources more
      effectively.

      Optical coherence tomography (OCT) is a kind of optical imaging medical system. It generates
      images by detecting the variations in refractive indexes of the various components in soft
      tissues. Apollo Medical Optics, Ltd. (AMO)'s OCT device (ApolloVue™ S100 image system,
      Viper1-S003) acquires real-time in vivo skin tissue tomograms with cellular resolution which
      provides a non-invasive, non-radioactive and rapid image acquisition.

      In this study, AMO's OCT will be used to observe features in tomograms of primary cutaneous
      amyloidosis and that of other indistinguishable diseases, compare the correspondence of
      tomograms with pathological sections, induct features in tomograms specific to primary
      cutaneous amyloidosis and other indistinguishable diseases, and further establish an OCT
      database of primary cutaneous amyloidosis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 8, 2019</start_date>
  <completion_date type="Anticipated">November 4, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 4, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with clear tissue characteristics of amyloidosis and/or other pigmented diseases in tomograms</measure>
    <time_frame>1 year</time_frame>
    <description>Number of subjects with clear tissue characteristics of tomograms will be compared to that with unclear tissue characteristics to identify the effect of the OCT on scanning amyloidosis and other pigmented diseases at study completion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with the distinction between skin lesion and normal skin in tomograms</measure>
    <time_frame>1 year</time_frame>
    <description>Number of subjects with the distinction between skin lesion and normal skin in tomograms will be compared to that with no distinction to verify the specific diseases that can be distinguished from normal skin by the OCT at study completion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with the distinction between amyloidosis and other pigmented diseases in tomograms</measure>
    <time_frame>1 year</time_frame>
    <description>Number of subjects with the distinction between amyloidosis and other pigmented diseases in tomograms will be compared to that with no distinction to verify the effect of the OCT on distinguishing amyloidosis from other pigmented diseases at study completion.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Amyloidosis</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <description>Patients with amyloidosis and other indistinguishable diseases</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ApolloVue™ S100 image system, Viper1-S003</intervention_name>
    <description>The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for experimental group.</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The population from experimental group will be selected.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with suspected primary cutaneous amyloidosis and other
             indistinguishable diseases

          -  Patients with no open wounds

        Exclusion Criteria:

          -  Patients with a transcutaneous infectious disease

          -  Patients under the age of 20

          -  Vulnerable populations, including: pregnant women, handicapped, and homelessness

          -  Patient cannot cooperate in examination
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ding-Dar Lee, M.D., Ph. D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Veterans General Hospital, Taiwan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hsin Cheng,, CRA</last_name>
    <phone>+886-2-87523198</phone>
    <phone_ext>103</phone_ext>
    <email>hsin@mdamo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei City</city>
        <state>Beitou District</state>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ding-Dar Lee, M.D., Ph. D.</last_name>
      <phone>+886-938593530</phone>
      <email>ddlee@vghtpe.gov.tw</email>
    </contact>
    <investigator>
      <last_name>Ding-Dar Lee, M.D., Ph. D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yun-Ting Chang, M.D., Ph. D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chih-Chiang Chen, M.D., Ph. D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Chuang YY, Lee DD, Lin CS, Chang YJ, Tanaka M, Chang YT, Liu HN. Characteristic dermoscopic features of primary cutaneous amyloidosis: a study of 35 cases. Br J Dermatol. 2012 Sep;167(3):548-54. doi: 10.1111/j.1365-2133.2012.11066.x.</citation>
    <PMID>22632408</PMID>
  </reference>
  <reference>
    <citation>Lei W, Ai-E X. Reflectance confocal microscopy for the characterization of primary cutaneous amyloidosis: a pilot study. Skin Res Technol. 2017 Aug;23(3):441-443. doi: 10.1111/srt.12343. Epub 2017 Jan 12.</citation>
    <PMID>28083882</PMID>
  </reference>
  <reference>
    <citation>Esmat SM, Fawzi MM, Gawdat HI, Ali HS, Sayed SS. Efficacy of different modes of fractional CO2 laser in the treatment of primary cutaneous amyloidosis: A randomized clinical trial. Lasers Surg Med. 2015 Jul;47(5):388-95. doi: 10.1002/lsm.22361. Epub 2015 May 6.</citation>
    <PMID>25946210</PMID>
  </reference>
  <reference>
    <citation>Al Yahya RS. Treatment of primary cutaneous amyloidosis with laser: a review of the literature. Lasers Med Sci. 2016 Jul;31(5):1027-35. doi: 10.1007/s10103-016-1917-8. Epub 2016 Mar 16. Review.</citation>
    <PMID>26984345</PMID>
  </reference>
  <reference>
    <citation>Chang CK, Tsai CC, Hsu WY, Chen JS, Liao YH, Sheen YS, Hong JB, Lin MY, Tjiu JW, Huang SL. Errata: Segmentation of nucleus and cytoplasm of a single cell in three-dimensional tomogram using optical coherence tomography. J Biomed Opt. 2017 Mar 1;22(3):39801. doi: 10.1117/1.JBO.22.3.039801.</citation>
    <PMID>28300273</PMID>
  </reference>
  <reference>
    <citation>Chiu YK, Chen WL, Tsai CT, Yang CH, and Huang SL. A high en-face resolution AS-OCT providing quantitative ability to measure layered corneal opacities. European Conferences on Biomedical Optics, Munich Germany, 25-29, 2017.</citation>
  </reference>
  <reference>
    <citation>Wang SC, Hsu CY, Yang TT, Jheng DY, Yang TI, Ho TS, Huang SL. Laser-diode pumped glass-clad Ti:sapphire crystal fiber laser. Opt Lett. 2016 Jul 15;41(14):3217-20. doi: 10.1364/OL.41.003217.</citation>
    <PMID>27420499</PMID>
  </reference>
  <reference>
    <citation>Wang SC, Yang TI, Jheng DY, Hsu CY, Yang TT, Ho TS, Huang SL. Broadband and high-brightness light source: glass-clad Ti:sapphire crystal fiber. Opt Lett. 2015 Dec 1;40(23):5594-7. doi: 10.1364/OL.40.005594.</citation>
    <PMID>26625059</PMID>
  </reference>
  <reference>
    <citation>Tsai CC, Chang CK, Hsu KY, Ho TS, Lin MY, Tjiu JW, Huang SL. Full-depth epidermis tomography using a Mirau-based full-field optical coherence tomography. Biomed Opt Express. 2014 Aug 8;5(9):3001-10. doi: 10.1364/BOE.5.003001. eCollection 2014 Sep 1.</citation>
    <PMID>25401013</PMID>
  </reference>
  <reference>
    <citation>Ho TS, Yeh P, Tsai CC, Hsu KY, Huang SL. Spectroscopic measurement of absorptive thin films by spectral-domain optical coherence tomography. Opt Express. 2014 Mar 10;22(5):5675-83. doi: 10.1364/OE.22.005675.</citation>
    <PMID>24663908</PMID>
  </reference>
  <reference>
    <citation>Cheng NC, Hsieh TH, Wang YT, Lai CC, Chang CK, Lin MY, Huang DW, Tjiu JW, Huang SL. Cell death detection by quantitative three-dimensional single-cell tomography. Biomed Opt Express. 2012 Sep 1;3(9):2111-20. Epub 2012 Aug 13.</citation>
    <PMID>23024905</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 22, 2019</study_first_submitted>
  <study_first_submitted_qc>August 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>August 22, 2019</last_update_submitted>
  <last_update_submitted_qc>August 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>optical coherence tomography (OCT)</keyword>
  <keyword>amyloidosis</keyword>
  <keyword>pigmented diseases</keyword>
  <keyword>skin diseases</keyword>
  <keyword>dermatology</keyword>
  <keyword>pathology</keyword>
  <keyword>H&amp;E stain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skin Diseases</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

